“Myriamed has, with its unrivaled expertise in induced pluripotent stem cell technologies, been a strong and reliable partner for many years with unique proprietary capabilities to create beyond the state-of-the-art patient-in-the dish models. With now a set of fully validated AI-powered human-disease centric assays, we have made a huge leap forward towards the identification of novel targets, drugs and biomarkers for the treatment of dilated cardiomyopathies. We are excited to jointly continue to explore this opportunity with myriamed”.

“Myriamed pursues a truly important endeavor. Nothing less than a revolution in pre-clinical research.”

“This is a game changer.”

“Myriamed has done a great job supporting us and I am happy to recommend your services”.

“This will likely bring more candidates into the clinic with a better profile right from the start.”

"In our current work at KIST Europe on Advanced Animal Testing (AAT) and New Approach Methodologies (NAMs), the reliability of every functional assay depends on the quality of the starting cell material. myriamed's human iPSC-derived cardiomyocytes consistently meet this bar, with excellent purity, high viability, and remarkable batch-to-batch reproducibility, complemented by the strong scientific engagement of their team. Having first worked with them during a myopathy drug discovery project at a French biotech startup, I have seen this consistency hold true across years and across both wild-type and patient-derived lines. myriamed is a partner I trust and recommend without hesitation."

Clyde Biosciences has used Myriamed human iPSC-derived cardiomyocytes in its service offering. With more than 10 years’ experience using commercial cardiomyocyte cell lines from multiple manufacturers, we routinely evaluate electrical activity, contractility, and cell viability. On this basis, we are pleased to recommend Myriamed cardiomyocyte products for studies of cardiomyocyte responses over acute and chronic timescales of 7–10 days. Electrophysiological analysis showed a predominantly ventricular phenotype, with consistent spontaneous rates and appropriate contraction time courses. The cells also transfected reliably and remained stable for several days in serum-free media, making them well suited to use as a commercial cell line for both acute and chronic studies.